RAQUEL
RIVERA DÍAZ
Profesora asociada
Pedro
Herranz Pinto
Publicaciones en las que colabora con Pedro Herranz Pinto (10)
2024
2023
-
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345
2022
-
Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life
Dermatologic Therapy, Vol. 35, Núm. 10
2021
-
Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study
Journal of the European Academy of Dermatology and Venereology
2020
-
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829
-
The Use of Apremilast in Psoriasis: A Delphi Study
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 2, pp. 115-134
2015
-
¿Es útil el estudio de la inmunogenicidad en los tratamientos biológicos en psoriasis?
Medicina Cutanea Ibero-Latino-Americana, Vol. 43, Núm. 1, pp. 10-17
2014
-
Clinical significance of immunogenicity in biologic therapy
Actas Dermo-Sifiliograficas, Vol. 105, Núm. 1, pp. 1-4